Researchers reveal mechanisms of how CDK12 alterations drive prostate cancer development

When researchers at the University of Michigan Rogel Cancer Center first identified a new subtype of aggressive prostate cancer, they knew they needed to understand how this genetic alteration was driving cancer and how to target it with treatment.

Tilray Cannabis Revenue Falls 13% in FY25-Q1

Tilray Brands Reports Q1 2025 Financial Results Tilray Achieves 13% Year-Over-Year Growth, Generating Record Q1 Net Revenue of $200 Million Q1 Gross Margin Increases Over

October 10, 2024

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression | Psychedelic Invest

NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment

April 24, 2024

AbbVie purchases neuroscience developer Cerevel for $8.7 billion

Abbvie announced Wednesday that it will purchase Cerevel Therapeutics and its pipeline of experimental neurological and psychiatric medications for $8.7 billion. The deal marks the

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.